Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SHP2 is a protein tyrosine phosphatase that promotes RAS signaling through multiple mechanisms, including facilitation of SOS1-mediated nucleotide exchange and regulation of KRAS conformational dynamics through dephosphorylation of Tyr32 and Tyr64 [8,9].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Src homology region 2 domain-containing phosphatase 2 (SHP2) is a receptor-free protein-tyrosine phosphatase and regulates proliferation by activating the RAS–MAPK–ERK signaling pathway.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1983 · Cited by 221
RetractedRETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., & Cheng, S. (2011) · Oncogene · doi:10.1038/onc.2011.436 · Cited by 78
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citationThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
The Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Research works printed but not linked: 1
- Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).
Cited by
Items 101–200 of 265
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
Heynen, G. J. J. E., Lisek, K., Vogel, R., Wulf-Goldenberg, A., Alcaniz, J., Montaudon, É., Marangoni, E., & Birchmeier, W. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01521-3 · Cited by 23
Liu, W.-S., Zhao, J., Guo, X., Lu, S.-Z., Li, W., & Li, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115585 · Cited by 24
Targeting phosphatases: From molecule design to clinical trials
Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 26
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
Jenkins, C., Luty, S. B., Maxson, J. E., Eide, C. A., Abel, M. L., Togiai, C., Nemecek, E. R., Bottomly, D., McWeeney, S. K., Wilmot, B., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aao5617 · Cited by 23
After 95 years, it's time to eRASe JMML
Meynier, S., & Rieux‐Laucat, F. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100652 · Cited by 24
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Than, M. T., O’Hara, M. H., Stanger, B. Z., & Reiss, K. A. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0519 · Cited by 23
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 24
The RAS oncogene in brain tumors and the involvement of let-7 microRNA
Messina, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09439-z · Cited by 25
“In particular, the KRAS oncogene is strongly involved in tumourigenesis in glioblastomas [75, 78, 79, 80], although KRAS mutations are almost absent in malignant gliomas [81].”
BackgroundCsermely, P., Korcsmáros, T., & Nussinov, R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.005 · Cited by 25
CNKSR1 serves as a scaffold to activate an EGFR phosphatase via exclusive interaction with RhoB-GTP
Nishiyama, K., Maekawa, M., Nakagita, T., Nakayama, J., Kiyoi, T., Chosei, M., Murakami, A., Kamei, Y., Takeda, H., Takada, Y., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202101095 · Cited by 21
“Exceptionally, several protein tyrosine phosphatases such as PTPN11 (alias SHP2) and PTP4A3 function as oncogenes (Bunda et al, 2015; den Hollander et al, 2016).”
The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness
Ha, J. R., Siegel, P. M., & Ursini‐Siegel, J. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25561 · Cited by 23
“SHP2 is able to de-phosphorylate this tyrosine residue and tip the balance in favor of Ras/Raf/MAPK activation [Bunda et al., 2015].”
BackgroundFunctional interrogation and therapeutic targeting of protein tyrosine phosphatases
Krabill, A. D., & Zhang, Z. (2021) · Biochemical Society Transactions · doi:10.1042/bst20201308 · Cited by 21
Self-citationPHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras
Wang, J., Yao, N., Hu, Y., Lei, M., Wang, M., Yang, L., Patel, S., Li, X., Liu, K., & Dong, Z. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04538-1 · Cited by 21
“tyrosine 32 phosphorylation has two important effects on Ras signaling: phosphorylation inhibits the binding of the effector protein Raf while increasing the binding of the GAP protein leading to enhanced GTP hydrolysis [25].”
BackgroundTargeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance
Zhao, Y., & Jiang, L. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.008 · Cited by 22
Li, X., Pang, J., Xue, W., Wang, Y., Tian, T., Elgehama, A. M., Wu, X., Wu, X., Sun, Y., Qiu, H.-X., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.044 · Cited by 22
Advancements in gene therapies targeting mutant KRAS in cancers
Wang, Y., Bui, T. A., Yang, X., Hutvágner, G., & Deng, W. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10243-9 · Cited by 23
“SHP2, a protein tyrosine phosphatase, plays a crucial role in KRAS activation by facilitating GRB2-SOS1 complex recruitment and dephos-phorylating substrates to positively impact KRAS activation [11, 12].”
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Sun, B., Jensen, N. R., Chung, D., Yang, M., LaRue, A. C., Cheung, H. W., & Wang, Q. (2019) · Europe PMC (PubMed Central) · Cited by 20
Tripathi, R. K. P., & Ayyannan, S. R. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13807 · Cited by 18
“Figure 10 enlists some representative SHP2 inhibitors targeting either the active site and demonstrating better efficacy in intracranial xenograft glioma models (Bunda et al., 2015; Zeng et al., 2014; Zhang et al., 2010) or showing allosteric binding mode of phosphatase inhibition (Chen et al.”
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3691 · Cited by 17
Sinnett‐Smith, J. W., Anwar, T., Reed, E. F., Teper, Y., Eibl, G., & Rozengurt, E. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0964 · Cited by 18
Kandjani, O. J., Yaqoubi, S., Vahdati, S. S., Borhannejad, B., Dastmalchi, S., & Alizadeh, A. A. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115182 · Cited by 18
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Kano, Y., Suenaga, M., & Uetake, H. (2023) · Current Oncology · doi:10.3390/curroncol30070480 · Cited by 18
“Another novel strategy is a combination with the inhibition of protein tyrosine phosphatase SHP2 that promotes the MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis [64,73,74].”
BackgroundSelf-citationYang, F., Xu, M., Wang, S., Song, L., Yu, D., Li, Y., Cao, R., Zhang, X., Chen, Z., Zhang, Q., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222881 · Cited by 17
“Recent research found that GBM tumors exhibit significantly higher levels of phosphorylated SHP2 compared with low-grade gliomas and their normal counterparts.(36) The dysregulation of SHP2 in GBM has potently stronger proliferation and transformation ability.”
BackgroundSHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
Huda, S., Cao, M., Rosa, A. D., Woodhall, M. R., Cruz, P. M. R., Cossins, J., Maestri, M., Ricciardi, R., Evoli, A., Beeson, D., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000645 · Cited by 17
“macologic inhibition of SHP2 has already demonstrated efficacy in the treatment of a mouse glioma xenograft model.(18)”
MethodProteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
Atomistic ensemble of active SHP2 phosphatase
Anselmi, M., & Hub, J. S. (2023) · Communications Biology · doi:10.1038/s42003-023-05682-5 · Cited by 17
Protein Phosphatases—A Touchy Enemy in the Battle Against Glioblastomas: A Review
Tomiyama, A., Kobayashi, T., Mori, K., & Ichimura, K. (2019) · Cancers · doi:10.3390/cancers11020241 · Cited by 19
“The major signaling pathway regulated by SHP2 is the Ras-Raf-ERK (MAPK) cascade [33,80–84].”
BackgroundAn Integrated Proteomic Strategy to Identify SHP2 Substrates
Zhu, P., Wu, X., Zhang, R., Hsu, C., Zhang, Z., & Tao, W. A. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00481 · Cited by 18
Self-citationKoschut, D., Ray, D., Li, Z., Giarin, E., Groet, J., Alić, I., Kham, S. K. Y., Chng, W. J., Ariffin, H., Weinstock, D. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01567-7 · Cited by 15
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
NMR in integrated biophysical drug discovery for RAS: past, present, and future
Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 16
“8.2, RAS can be tyrosyl phosphorylated by Src kinase and dephosphorylated by SHP2 phosphatase (Bunda 2014, 2015).”
BackgroundInfluentialŠolman, M., Woutersen, D. T. J., & den Hertog, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1046415 · Cited by 15
“The direct activation of RAS by dephosphorylation of Tyr 32 on RAS has also been reported (Bunda et al., 2015).”
Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 15
PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
Amante, R. J., Jehanno, C., Silva, D. D., Coissieux, M., Ackerknecht, M., Romanet, V., Sethi, A., Hamelin, B., Preca, B., Piscuoglio, S., et al. (2023) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-023-09539-9 · Cited by 14
“While PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) is rarely mutated in solid tumors, SHP2 is activated downstream of several oncogenic signals [9, 10].”
BackgroundHou, Q., Jiang, W., Li, W., Huang, C., Yang, K., Chen, X., Huang, M., Shu, C., Luo, G., Sun, H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00992 · Cited by 14
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy
Scheiter, A., Lu, L., Gao, L. H., & Feng, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-013740 · Cited by 19
Bruno, J. L., Shrestha, S. B., Reiss, A. L., Saggar, M., & Green, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01422-5 · Cited by 13
“The active conformation of Shp-2 in turn leads to RAS/MAPK pathway upregulation [7, 13].”
BackgroundThe Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?
Saint-Laurent, C., Mazeyrie, L., Tajan, M., Paccoud, R., Castan‐Laurell, I., Valet, P., Édouard, T., Pradère, J., Dray, C., & Yart, A. (2022) · Biomedicines · doi:10.3390/biomedicines10092139 · Cited by 14
Ma, J., Tang, W., Gu, R., Hu, F., Zhang, L., Wu, J., & Xu, G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.555006 · Cited by 14
Liu, X., Zhang, Z., Yuan, J., Yu, J., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396719 · Cited by 13
Self-citationLevin, J. B., & Borodinsky, L. N. (2022) · Cell Calcium · doi:10.1016/j.ceca.2022.102540 · Cited by 12
“Wu R, Li H, Li T, Zhang Y, Zhu D, Myostatin regulates miR-431 expression via the RasMek-Erk signaling pathway, Biochem.”
BackgroundInfluentialTargeting SHP2 Signaling in Lung Cancer
Imbody, D. J., Arce-Ruiz, K. M., Solanki, H. S., Haura, E. B., & Pellini, B. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.009 · Cited by 12
Ma, C., Zhao, J., Zhang, X., Ding, C., Hao, H., Ji, Y., Li, L., Guo, Z., & Liu, W. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127845 · Cited by 12
Single-cell sensor analyses reveal signaling programs enabling Ras-G12C drug resistance
Zhang, J. Z., Ong, S., Baker, D. A., & Maly, D. J. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01684-4 · Cited by 14
Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism
Bajia, D., Bottani, E., & Derwich, K. (2022) · Cells · doi:10.3390/cells11193099 · Cited by 13
“Apart from SOS, another key player, the tyrosine phosphatase SHP2, can activate Ras by dephosphorylating a series of inhibitory kinase proteins on docking proteins (src regulatory proteins) or RAS itself [12,13].”
BackgroundEvaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Sisler, D. J., Hinz, T. K., Le, A. T., Kleczko, E. K., Nemenoff, R. A., & Heasley, L. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094123 · Cited by 11
New insights into RAS in head and neck cancer
Jagadeeshan, S., Novoplansky, O., Cohen, O. M., Kurth, I., Heß, J., Rosenberg, A. J., Grandis, J. R., & Elkabets, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188963 · Cited by 14
Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation
Jeon, S. M., Lim, J. S., Park, S. H., Kim, H. J., Kim, H., & Lee, J. (2022) · International Journal of Oral Science · doi:10.1038/s41368-022-00168-2 · Cited by 11
“For instance, PD-1 inhibits TCR-mediated activation of Ras through an unknown mechanism in T cells,(36) in contrast; PD-1 signaling enhances Ras activation through phosphatase activity of SHP2 in tumor cells.(37,38) In addition to SHP2 phosphatase activity, it functions as an adapter that binds to receptor tyrosine ki…”
BackgroundSütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
Valencia-Sama, I., Kee, L., Christopher, G., Ohh, M., Layeghifard, M., Shlien, A., Hayes, M. N., & Irwin, M. S. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0234 · Cited by 10
Self-citationHale, A. J., & den Hertog, J. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00515-17 · Cited by 10
“substrates (31, 58) and thus have inadvertent dominant effects.”
BackgroundNatural product-inspired molecules for covalent inhibition of SHP2 tyrosine phosphatase
Liang, W., Krabill, A. D., Gallagher, K. S., Muli, C. S., Qu, Z., Trader, D. J., Zhang, Z., & Dai, M. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.133918 · Cited by 9
Self-citationMarasco, M., Kirkpatrick, J., Carlomagno, T., Hub, J. S., & Anselmi, M. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.02.023 · Cited by 9
“Currently, SHP2 represents a key target for anticancer therapy [22 – 29].”
BackgroundTumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
Chen, H., Cresswell, G. M., Libring, S., Ayers, M. G., Miao, J., Zhang, Z., Solorio, L., Ratliff, T. L., & Wendt, M. K. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0117 · Cited by 10
Self-citationSetting sail: Maneuvering SHP2 activity and its effects in cancer
Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 10
Zheng, L., Wang, Y., Jiang, Z., Chen, S., Cao, X., Huang, X., Luo, R., Zheng, L., Li, Q., Tu, L., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117745 · Cited by 8
Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells
Wolter, J. K., Valencia-Sama, I., Osborn, A. J., Propst, E. J., Irwin, M. S., Papsin, B. C., & Wolter, N. E. (2022) · Microvascular Research · doi:10.1016/j.mvr.2022.104397 · Cited by 9
Ma, Y., Li, W., Sun, T., Zhang, L., Lu, X., Yang, B., & Wang, R. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105648 · Cited by 8
Ayanlaja, A. A., Chang, M., Lalwani, K., Ioannou, M., Wang, J., Jagtap, S., Yang, Y., Lucas, C. G., Levy, J. M. M., Gartrell, R. D., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf170 · Cited by 7
“20,21 SHP2-dependent RAS activation can drive adaptive resistance to MEK inhibitors in some cancers, and SHP2 inhibition with small molecule inhibitors (SHP2i) can prevent or overcome adaptive resistance to MEK inhibitors, 22–25 making them promising clinical candidates when combined with other…”
Yan, H.-L., Jiang, M., Yang, F., Tang, X., Lin, M., Zhou, C., Tan, Y., & Liu, D. (2022) · Molecules · doi:10.3390/molecules27175469 · Cited by 7
“Predicting the pharmacokinetic properties is beneficial for understanding and predicting the biological action of drugs, such as toxicity or therapeutic effects [16].”
BackgroundSHP2–EGFR States in Dephosphorylation Can Inform Selective SHP2 Inhibitors, Dampening RasGAP Action
Liu, Y., Jang, H., & Nussinov, R. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c00873 · Cited by 7
Li, N., Liu, C., Zhang, W., & Rao, G. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258913231019113814 · Cited by 8
Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment
Han, X., Wang, W., Wang, R., Zhang, W., Zhu, L., Xu, Q., Guo, W., & Gu, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149812 · Cited by 7
Wang, K., Zhang, X., Hu, Y., Guo, J., Shen, G., Zhang, K., Jiang, S., & Wang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117036 · Cited by 7
Regulation of Ras-GTPase Signaling and Localization by Post-Translational Modifications
Nair, A., & Saha, B. (2023) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases1020007 · Cited by 9
“Phospho-Tyr32 can be dephosphorylated by SHP2 (SH2-containing protein tyrosine phosphatase-2 phosphatase), which activates H/N-Ras and reinstates Ras downstream signaling by binding to Raf [75].”
BackgroundPatient-Centric Approaches for Phase I Combination Trials Come on Stage
Hernando‐Calvo, A., & Garralda, E. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0534 · Cited by 8
“Preclinical data support dual inhibition of the pathway to suppress intrinsic mechanisms of resistance by decreasing MAPK signaling, resulting in decreased tumor cell proliferation and tumor growth (4).”
BackgroundInfluentialDu, T., Hu, X., Hou, Z., Wang, W., You, S., Wang, M., Ji, M., Xue, N., & Chen, X. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05034-w · Cited by 7
“…tyrosine-protein phosphatase non-receptor type 11 ( Ptpn11 )-encoded Src homology 2 containing protein tyrosine phosphatase 2 (SHP2) dephosphoryl-ates RAS protein, restores the canonical GTPase cycle, augments RAS binding affinity to effectors and, consequently, promotes MAPK signaling [12].”
Recent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 7
Compartmentalisation in cAMP signalling: A phase separation perspective
Folkmanaite, M., & Zaccolo, M. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70145 · Cited by 6
Otani, R., Ikegami, M., Yamada, R., Yajima, H., Kawamura, S., Shimizu, S., Tanaka, S., Takayanagi, S., Takami, H., & Yamaguchi, T. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04411-6 · Cited by 6
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 7
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition
Lai, X., Lui, S. K. L., Lam, H. Y., Adachi, Y., Sim, W. J., Vasilevski, N., Armstrong, N. J., Bridgeman, S. C., Main, N., Tan, T. Z., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00486-6 · Cited by 6
Zhang, L., Ma, W., Chen, Y., Chen, Z., Wang, F., & Xu, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107661 · Cited by 7
An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma
Tannous, B. A., & Badr, C. E. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz176 · Cited by 7
Ma, Y., Wenyu, Y., Zhou, L., Li, L., Wu, J., Li, W., S, D. A., Ma, Y., & Wang, R. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10286-4 · Cited by 6
Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma
Xu, L., Wang, P., Zhang, W., Li, W., Liu, T., & Che, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757498 · Cited by 6
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
Song, Y., Yang, X., & Yu, B. (2022) · Pharmaceutical Fronts · doi:10.1055/s-0042-1743411 · Cited by 6
van Vlimmeren, A. E., Tang, L. C., Jiang, Z., Iyer, A., Voleti, R., Krismer, K., Gaublomme, J. T., Jovanović, M., & Shah, N. H. (2025) · EMBO Reports · doi:10.1038/s44319-025-00674-4 · Cited by 5
“While SHP2 functions in many signaling pathways, its role in disease has largely been linked to dysregulation of the Ras/MAPK pathway (Asmamaw et al, 2022; Agazie and Hayman, 2003b; Montagner et al, 2005; Bunda et al, 2015; Dance et al, 2008).”
Insights into RAS-driven melanoma and its therapeutic implications
Chatziioannou, E., Lallas, K., Sinnberg, T. W., Niessner, H., Stratigos, A., Flatz, L., & Amaral, T. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103090 · Cited by 7
Kambaru, A., & Chaudhary, N. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210810094739 · Cited by 5
Guo, Y. L., Xu, Y., Dong, X., & Zhang, J. (2021) · ChemistrySelect · doi:10.1002/slct.202100186 · Cited by 6
Engineering SHP2 Phosphatase for Optical Control
Ryan, A., Janosko, C. P., Courtney, T. M., & Deiters, A. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00387 · Cited by 5
Enzyme Is the Name—Adapter Is the Game
Huber, M., & Brummer, T. (2024) · Cells · doi:10.3390/cells13151249 · Cited by 4
“The majority of these substrates remain ill-defined [80], and its positive influence on RAS/ERK pathway activation appears to be manifold, including the dephosphorylation of a tyrosine residue in RAS, which enhances RAF recruitment in its unmodified state [81].”
BackgroundJohnson, M. L., Wolf, B. B., Wang, J. S.-Z., Philipovskiy, A. V., Shapiro, G. I., Bockorny, B., Guo, W., Shen, J., Jen, K. Y., LeRose, M., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0466 · Cited by 4
Moon, D. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050309 · Cited by 4
“In the PI3K/AKT signaling pathway, SHP2’s role is context-dependent and influenced by the specific RTKs involved [9,10,41].”
Xie, T., Zhang, S., Shen, W., Zhang, G., Guo, R., Zhang, W., Cao, Y., Pan, Q., Liu, F., Sun, Y., et al. (2022) · Genes · doi:10.3390/genes13101902 · Cited by 4
“SHP2 binds to RAS and dephosphorylates to increase RAS-RAF binding and activate downstream RAS/ERK/MAPK proliferative signaling, suggesting that SHP2 was a direct activator of RAS [23].”
BackgroundFrom Stem to Sternum: The Role of Shp2 in the Skeleton
Jensen, N. R., Kelly, R. R., Kelly, K. D., Khoo, S. K., Sidles, S. J., & LaRue, A. C. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01042-3 · Cited by 4
“In this model, SHP2-mediated dephosphorylation of RAS Y32 relieves an inhibitory feedback mechanism to promote RAS-GTP cycling and enhanced pathway activation [34] (Fig.”
BackgroundDias, M. H., Liudkovska, V., Bleijerveld, O. B., Velds, A., Bernards, R., & Cieśla, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.12.548685 · Cited by 5
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Falchook, G. S., Xavier, C. B., Veenhuyzen, D. F. V., Malhotra, J. D., Sadeghi, S., Kalebasty, A. R., Wood, L., Rahman, F., Li, E., Pak, Y., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01340-1 · Cited by 4
“…mutated oncogenes in patients with cancers 1 , and the ubiquitous tyrosine phosphatase SHP2 (also known as PTPN11) has emerged as a major regulator of the RAS pathway and subsequently the downstream receptor tyrosine kinase – mediated mitogen-activated protein kinase (MAPK) signaling pathway 2 .”
Far-reaching effects of tyrosine64 phosphorylation on Ras revealed with BeF3– complexes
Baumann, P., & Jin, Y. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01105-6 · Cited by 4
“Our results indicated that mono-phosphorylated Ras remained stable in buffer for over a week, rendering it suitable for subsequent crystallisation trials (Supplementary Figure 9).”
BackgroundInfluentialHe, C., Yu, J., Mao, S., Yang, S., Jiang, X., Huang, L., Li, M., He, Y., Zhang, X., & Xiang, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70231 · Cited by 3
Jin, L., Nara, H., Rahman, M., Takeda, Y., Araki, A., & Asao, H. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.187 · Cited by 3
“Recently, in EGF-induced signaling, SHP-2 was reported to dephosphorylate Ras to increase its association with Raf and activate the downstream ERK pathway (Bunda et al. 2015).”
Fink, J. C., Landry, D., & Webb, L. J. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00075 · Cited by 3
van Vlimmeren, A. E., Giglio, R. M., Jiang, Z., Lee, M., McFaline‐Figueroa, J. L., & Shah, N. H. (2026) · Science Advances · doi:10.1126/sciadv.aea9389 · Cited by 2
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2
“This discovery enabled the development of selective inhibitors that covalently bind the reactive cysteine residue to stabilize the inactive GDP-bound structure and impair interactions with Raf (11–17).”
Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2
Mahmood, S., Leiter, S. M., Phyu, P., Craven, C. L., Horan, G., Gains, J. E., Briggs, M., Blanco, E., Behjati, S., Watkins, J. A., et al. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31368 · Cited by 2
“The American Society of Pediatric Hematology/Oncology”
Seo, B. S., & Moon, D. O. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.71.12.5 · Cited by 1
“Among these, the non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene, commonly known as SHP2, plays a crucial role in mediating signals from growth factor receptors to downstream pathways, particularly the RAS/RAF/ERK cascade [2-4].”
Wang, Y., Wang, Y., Wu, R., Luo, H., Li, Y., Chen, X., Liu, K., Dong, Z., & Liu, H. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102096 · Cited by 1
Metadata
- Authors
- Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Ohh, Michael
- Venue
- Nature Communications
- Published
- 2015-11-30
- Volume
- 6
- Issue
- 1
- Pages
- 8859-8859
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4674766
- OpenAlex
- W2254051095
- Cited by
- 249
- References
- 63
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 29 · 2023: 36 · 2022: 30 · 2021: 30 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 21 · 2016: 10
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA69202, R01CA069202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- SHP2, protein tyrosine phosphatase, Raf activation, glioblastoma, astrocytes, oncogenic Ras, therapeutic target, cell proliferation, tumor growth
- MeSH terms
- Animals, Cell Line, Female, Glioblastoma, Humans, Male, Mice, Inbred ICR, Phosphorylation, Oncogene Protein p21(ras), Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.